SNDX-275
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for SNDX-275, covering 2019-10-24 to 2023-07-06. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib [Phase 2]